QUIMATRYX, S.L.
- Biotech or pharma, therapeutic R&D
Quimatryx, S.L. a subsidiary of Oncomatryx, S.L., based in San Sebastian, Spain, develops novel drugs against epigenetic targets. Quimatryx is developing QTX153 (‘153) a novel, best-in-class oral HDAC inhibitor. ‘153 is a potent, highly-selective, blood-brain-barrier crossing-oral. small molecule non-hydroxamic HDAC6 inhibitor for the treatment of neurological disorders (including rare CNS indications Charcot Marie Tooth, Rett Syndrome and CIPN), as well as obesity, fibrosis and oncology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}